ATS 2024 Final Program

Click on the session title to view the speakers

155

MONDAY • MAY 20

P1297 Cortisol on the Clock: Systemic Circadian Disruption in Severe Alpha-1 Antitrypsin Deficiency P1298 Primary Spontaneous Pneumothorax as a Clinical Manifestation of Alpha-1 Antitrypsin Deficiency P1299 KRRO-110, An RNA Editing Oligonucleotide Encapsulated in a Lipid Nanoparticle (LNP) Delivered to Liver Cells for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

B50 EMERGING RESEARCH IN

ALPHA-1-ANTITRYPSIN DEFICIENCY

9:15 a.m. - 4:15 p.m.

San Diego Convention Center Area K (Hall H, Ground Level)

Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P1287 SERPINA1 Gene Polymorphism: Analysis of Patients Over 2 Years P1288 Alpha-1 Research Registry: Comparison of Characteristics of Augmented Versus Non-Augmented Patients With Alpha-1 Antitrypsin Deficiency in the United States P1289 Long-term Follow-up of Pi*ZZ Alpha-1 Antitrypsin Deficient Patients Receiving Intravenous Alpha-1 Antitrypsin Augmentation Therapy P1290 Family Screening in ZZ Alpha-1 Antitrypsin Deficiency - Exposing the Hidden Burden of Liver Disease P1291 Longitudinal SF-36 Physical and Mental Health Trajectories in Alpha-1 Antitrypsin Deficiency-associated Lung Disease P1292 Characteristics Associated With SF-36 in Alpha-1 Antitrypsin Deficiency-related Lung Disease: A Cross-sectional Analysis P1293 Alpha-1 Anti-Trypsin Carrier Genotype and the Risk of COPD Exacerbations: A Methodological Abstract P1294 Bronchiectasis and Disease Progression in Alpha-1 Antitrypsin Deficiency P1295 Optimizing Bronchoalveolar Lavage in Chronic Obstructive Pulmonary Disease and Alpha-1 Antitrypsin Deficiency P1296 Effectiveness of Bronchoscopic Lung Volume Reduction With Zephyr Endobronchial Valves in Alpha-1 Antitrypsin Deficient Chronic Obstructive Pulmonary Disease Patients Versus Chronic Obstructive Pulmonary Disease Patients Without Alpha-1 Antitrypsin Deficiency: A Matched Case-control Study

CLINICAL THEMATIC POSTER SESSION

B51 LEVERAGING ADMINISTRATIVE AND LARGE DATASETS TO UNDERSTAND COPD EPIDEMIOLOGY 9:15 a.m. - 4:15 p.m. San Diego Convention Center Area E (Hall A-B2, Ground Level) Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P578 Identifying Clinical Predictors of Chronic Hypercapnia in Patients With Chronic Obstructive Pulmonary Disease P579 Identification of Sleep Phenotypes in COPD Using Machine Learning-based Cluster Analysis P580 Embedded Electronic Health Record Algorithm Predicts COPD P581 Development of a Curated Pulmonary Datamart and Application to Identify Patients With COPD and Asthma With Serologic Criteria for Targeted Biologic Therapy P582 Clinical Phenotype and Modifiable Factors Associated With Bronchodilator Response in Patients With Chronic Obstructive Pulmonary Disease in Primary Care P583 Clinical and Economic Burden of COPD in Patients Poorly Controlled on LABA/LAMA or Inhaled Triple Therapy in Germany - A Retrospective Claims Data Analysis

ATS 2024 Conference Program • San Diego, CA